CYCN
Cyclerion Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$12.51M
P/E Ratio
—
EPS
$-1.11
Beta
0.89
52W High
$8.48
52W Low
$1.03
50-Day MA
$1.80
200-Day MA
$2.08
Dividend Yield
—
Profit Margin
-170.10%
Forward P/E
—
PEG Ratio
—
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $2.07M |
| Gross Profit (TTM) | $1.11M |
| EBITDA | $-9.58M |
| Operating Margin | -81.80% |
| Return on Equity | -39.30% |
| Return on Assets | -31.80% |
| Revenue/Share (TTM) | $0.65 |
| Book Value | $2.38 |
| Price-to-Book | 1.39 |
| Price-to-Sales (TTM) | 6.03 |
| EV/Revenue | 4.514 |
| EV/EBITDA | 0.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -43.20% |
| Shares Outstanding | $4.33M |
| Float | $3.49M |
| % Insiders | 24.26% |
| % Institutions | 7.28% |
Data last updated: 4/14/2026